![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 44, 31119-31122, October 29, 1999
From the Department of Biochemistry, University of California,
Riverside, California 92521
The p21-activated protein kinase The p21-activated protein kinases
(PAK)1 are activated by the
small G-proteins Rac 1 and Cdc42 (1-3). Three mammalian PAKs are
known: DNA damage is a major threat to cells; failure to repair the DNA before
cell division causes genomic instability or lethality and a
predisposition to cancer in multicellular organisms. Agents that induce
DNA damage such as ionizing radiation (IR), ultraviolet light (UV), or
chemotherapeutic drugs such as cis-platinum(II)diammine dichloride
(cisplatin) or cytosine In this study, IR and other DNA-damaging agents have been used to
examine whether Materials--
Cell culture media and reagents were purchased
from Life Technologies, Inc. Okadaic acid was from LC Laboratories.
Histone 4, leupeptin, pepstatin, and aprotinin were from Roche
Molecular Biochemicals. Wortmannin, AraC, cisplatin, and myelin basic
protein were from Sigma. Genistein was from Alexis Co. Ly 294002 was
from Calbiochem. RR-1 anti-PAK antibody was obtained as described
previously (7). Antibodies against Cell Culture and Treatment--
3T3-L1 mouse fibroblasts were
grown in Dulbecco's modified Eagle's medium supplemented with 10%
fetal calf serum. U937 leukemia cells were grown in RPMI 1640 medium
supplemented with glutamine and 10% fetal calf serum. Exponentially
growing cells were irradiated in a 137Cs Preparation of Total Extracts--
Cells were thawed in 0.5 ml
of freshly prepared lysis buffer (50 mM Tris/HCl, pH 7.5, 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 10 mM Assay of JNK Activity Assay--
JNK activity was determined after
precipitation of the protein kinase with glutathione
S-transferase-c-Jun bound to glutathione-Sepharose beads
prepared as described (19).
To examine whether The observed increase in When immunoprecipitates of Doses of 1 and 5 Gy of IR resulted in a temporal slowing of the growth
of 3T3-L1 cells; for doses of 20 and 100 Gy, the cells stopped dividing
and accumulated in the G2/M phase of the cell cycle. None
of the doses of IR used in the experiments induced significant
apoptosis in 3T3-L1 cells, even 48-h post-irradiation. Accordingly, no
Although the primary cellular effect of IR is the induction of double
strand DNA breaks, it also causes other changes (16). To examine if DNA
damage was the trigger for
COMMUNICATION
p21-activated Protein Kinase
-PAK Is Activated by Ionizing
Radiation and Other DNA-damaging Agents
SIMILARITIES AND DIFFERENCES TO
-PAK*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-PAK is
activated 2-5-fold in response to ionizing radiation (IR) in 3T3-L1
fibroblasts and U937 leukemia cells.
-PAK is activated in a dose-
and time-dependent manner. Doses from 1 to 100 Gy result in
significant stimulation of activity at 30 min, whereas maximal
stimulation is observed at 120 min after irradiation. UV (80 J/m2) and the DNA-damaging drugs cytosine
-D-arabinofuranoside (AraC) and cis-platinum(II)diammine
dichloride (cisplatin) also induce
-PAK activation. The activation
of
-PAK in response to IR or AraC is dependent on tyrosine kinase
and phosphoinositide 3-kinase activity, as demonstrated by use of the
inhibitors genistein and wortmannin; in contrast activation of
-PAK
by cisplatin and UV is not affected significantly by these inhibitors,
suggesting that
-PAK can be activated by more than one pathway in
response to different types of DNA damage. In contrast to
-PAK,
-PAK and JNK are activated only by cisplatin and UV in 3T3-L1 cells, suggesting differential regulation of the protein kinases. This is the
first time that members of the Ste20/PAK family of protein kinases have
been shown to be involved in the cellular response to IR and other
DNA-damaging agents.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-PAK (PAK1, 68 kDa),
-PAK (PAK3, 65 kDa), and
-PAK (PAK2, PAK I, 58-60 kDa).
-PAK is unique among the mammalian members of the PAK family, as it is activated by caspase cleavage during apoptosis and can induce some of the changes involved in this
death program (4-6).
-PAK appears to have cytostatic properties, as
injection of the active enzyme into frog embryos results in cleavage
arrest at mitotic metaphase (7).
-PAK is activated in response to
cell stress (8) and serum
starvation,2 in contrast to
the related
-PAK, which appears to be involved in the control of the
cytoskeletal architecture (9-11) and is activated by growth factors
(12) and insulin (13). When 3T3-L1 cells are subjected to hyperosmotic
stress,
-PAK is activated by a two-step mechanism involving
translocation to the particulate fraction and activation of the protein
kinase in a phosphoinositide 3-kinase
(PI3-kinase)-dependent manner (8).
-PAK involvement in
cell cycle regulation is supported by data showing that the protein
kinase phosphorylates and regulates Raf-1 (14).
-D-arabinofuranoside (AraC) lead
to activation of the DNA repair machinery of the cell and of different
signaling pathways that transiently inhibit the cell cycle. This
cytostatic response allows DNA repair prior to cell division
(15-18).
-PAK could be involved in the cytostatic response to
DNA damage. It is shown that
-PAK is activated in response to IR in
a dose- and time-dependent manner. UV and the DNA-damaging
drugs cisplatin and AraC also activate
-PAK, suggesting that
different types of DNA damage trigger the activation of the protein
kinase. The possible relationship between the observed
-PAK
activation and its described cytostatic properties is discussed.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-PAK (N19, C20) and
-PAK
(N20), peroxidase-coupled secondary antibodies, and protein G-agarose
were purchased from Santa Cruz Biotechnology. The enhanced
chemiluminescent (ECL) detection kit was from Amersham Pharmacia
Biotech. [
-32P]ATP was purchased from NEN Life Science
Products. All other chemicals were obtained from Sigma or Fisher Scientific.
irradiator
(MARK I; J. L. Shepherd & Associates, San Fernando, CA) at dose
rates of 352 Gy/min (for 100 Gy dose), 116 Gy/min (for 5 Gy dose), or
39.8 Gy/min (for 1 Gy dose). Control cells were treated exactly without
irradiation. The DNA-damaging drugs AraC and cisplatin were added to
the culture medium for the indicated times at a concentration of 50 µM. UV irradiation was carried out in a UV cross-linker
(FB-UVXL-1000; Fisher); the culture medium was removed during
irradiation. Control cells were treated exactly the same without
irradiation. Cells were incubated for the indicated times, harvested,
frozen in liquid nitrogen, and stored at
70 °C. When indicated,
the cells were preincubated for 15 min with 100 µM
genistein or 200 nM wortmannin (stock solutions in
Me2SO) before treatment. Control cells were mock-treated
with Me2SO.
-mercaptoethanol, phosphatase
inhibitors (50 mM NaF, 5 mM Na4P2O7, 2 mM
Na3VO4, 10 nM okadaic acid) and
protease inhibitors (40 µg/ml leupeptin, 40 µg/ml pepstatin, 40 µg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride))
plus 1% Nonidet P-40. After 10 min on ice, the lysate was centrifuged
at 16,000 × g for 10 min at 4 °C, and the
supernatant was collected. More than 95% of the
-PAK was extracted
as determined by Western blotting.
-PAK and
-PAK Activity After
Immunoprecipitation--
-PAK activity was assayed using histone 4 as substrate, after immunoprecipitation of the protein kinase with
anti-
-PAK N19 antibody.
-PAK activity was measured with myelin
basic protein as substrate after immunoprecipitation with anti-
-PAK
N20 antibody. The radioactivity incorporated into the protein
substrates was quantified using a PhosphorImager system.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-PAK activity was affected by IR,
exponentially growing 3T3-L1 mouse fibroblasts and U937 human leukemia cells were exposed to 5 and 100 Gy of
-radiation using a
137Cs source. After irradiation, the cells were incubated
for 120 min in a CO2 incubator, and lysed in buffer
containing 1% Nonidet P-40.
-PAK activity was determined following
immunoprecipitation of the protein kinase from cell extracts with
histone 4 as substrate. Fig.
1A shows that 120 min after
irradiation,
-PAK activity in 3T3-L1 cells was increased about
2-fold at doses of 5 and 100 Gy. In U937 cells, a dose of 100 Gy
induced a 4-5-fold increase in
-PAK activity, whereas 5 Gy had no
observable effect. As U937 cells undergo rapid apoptosis in response to
IR, 3T3-L1 cells were chosen as a model for this study.

View larger version (34K):
[in a new window]
Fig. 1.
Activation of
-PAK
by IR. 3T3-L1 and U937 cells were irradiated with a
137Cs
source, and incubated in a CO2
incubator for the indicated times.
-PAK activity was measured after
immunoprecipitation using histone 4 as substrate. A, histone
4 phosphorylated by
-PAK immunoprecipitated from control
(C) and irradiated cells (5 Gy, 100 Gy) at 120 min post-irradiation. The values shown are the
average ± S.E. of two different experiments expressed as
percentage of control. B,
-PAK activity in 3T3-L1 cells
at zero time (control) and at 30 and 120 min
post-irradiation. The average value from three different
experiments ± S.E. is shown. C, left panel,
-PAK
immunoprecipitated from control (C) and irradiated 3T3-L1
cells (1 Gy, 5 Gy) was used to phosphorylate
histone 4 (upper panel). Similar immunoprecipitates were
used for
-PAK quantification by Western blotting using anti-
-PAK
N19 antibody (lower panel). C, right
panel, Western blots of equal amounts of total protein from
control (C) and irradiated 3T3-L1 cells (1 Gy,
5 Gy) using Santa Cruz N19 antibody (N19) and
antibody to active phosphorylated
-PAK (RR-1), as
described (7).
-PAK activity in response to IR was both
dose- and time-dependent (Fig. 1B) with
significant stimulation of activity observed at 30 min with doses of 1, 5, and 100 Gy, suggesting a physiologically modulated response. Maximum
stimulation was observed 120 min after irradiation, as longer
incubation times after irradiation did not result in further increase
of
-PAK activity (data not shown).
-PAK were analyzed by Western blotting,
the same amount of
-PAK was detected in control and irradiated cells
(Fig. 1C, left panel), indicating a stimulation
of
-PAK activity in irradiated cells. This was supported further by
the use of an anti-
-PAK antibody (RR-1), which reacted
preferentially with the regulatory domain (6) of highly
autophosphorylated active
-PAK.3 Although in
response to IR no changes in total
-PAK protein were detected with
the N19 antibody (which recognizes both active and inactive
-PAK), a
higher level of
-PAK immunoreactivity was observed with the RR-1
antibody in irradiated cells as compared with control cells (Fig.
1C, right panel). This indicated that IR
stimulated
-PAK autophosphorylation and activation.
-PAK activation by caspase cleavage was observed by Western blot
analysis using antibodies against either the C or the N terminus of
-PAK (data not shown).
-PAK activation in response to IR, 3T3-L1
cells were incubated with two different DNA-damaging drugs or
irradiated with increasing doses of UV, and
-PAK activity was
determined with histone 4 as substrate after immunoprecipitation.
Cisplatin, which produces interstrand cross-links in the DNA (20), was a potent activator of
-PAK, with a
2.5- and 5-fold stimulation of activity after incubation for 30 and 120 min, respectively (Fig. 2). The antimetabolite AraC, which is
incorporated into the DNA and produces termination of DNA synthesis
(21), activated
-PAK around 2.5-fold at both 30 and 120 min of
incubation. UV, which induces mainly pyrimidine dimers in the DNA (18),
activated
-PAK up to 3-fold 120 min after irradiation at 80 J/m2, whereas 10 J/m2 had no effect on the
protein kinase activity (Fig. 2). Neither DNA-damaging drugs nor UV
resulted in cleavage of
-PAK by caspase, as determined by Western
blotting (data not shown). Thus, different types of DNA damage result
in activation of
-PAK, supporting the idea that DNA damage is the
trigger of
-PAK activation in response to IR.

View larger version (29K):
[in a new window]
Fig. 2.
Effects of UV radiation and the DNA-damaging
drugs cisplatin and AraC on the activity of
-PAK. 3T3-L1 cells were treated as described
and
-PAK activity was measured after immunoprecipitation using
histone 4 as substrate. Right, histone 4 phosphorylated by
-PAK immunoprecipitated from nontreated control cells
(C), cells incubated with 50 µM cisplatin or
AraC for 120 min (CisP, AraC), and cells
irradiated with the indicated doses of UV and incubated for 120 min
(UV). Left,
-PAK activity from control cells
(0 min), cells incubated with 50 µM
cisplatinum (CisP) or Ara C (AraC) for 30 or 120 min.
-PAK activity from control cells (0 min), and cells
irradiated with the indicated doses of UV at 30 or 120 min. The average
value ± S.E. of three independent experiments is shown.
To study further the physiological mechanisms of
-PAK activation by
DNA damage, 3T3-L1 cells were preincubated with or without the tyrosine
kinase inhibitor genistein or the PI3-kinase inhibitor wortmannin
before irradiation; DNA-damaging drugs
were present in the culture medium throughout the experiments (Fig. 3).
Short incubation times were used to avoid a direct effect of wortmannin or genistein on
-PAK activity. A significant inhibition of
-PAK activation by IR (5 Gy) was observed when genistein or wortmannin were
present (60 and 90%, respectively). Genistein and wortmannin also
abolished activation of
-PAK by AraC (65 and 100%, respectively). The PI3-kinase inhibitor Ly 294002 also inhibited
-PAK activation by
IR or AraC (data not shown), further supporting the involvement of
PI3-kinase activity in the activation of
-PAK. Cisplatin activation of
-PAK was not affected by wortmannin and only slightly affected by
genistein, whereas neither compound inhibited activation of
-PAK by
UV.
|
The fact that both genistein and wortmannin interfered with the
activation of
-PAK by IR and AraC indicated that tyrosine kinase and
PI3-kinase activity are essential upstream activators of
-PAK in
response to these DNA-damaging treatments. In contrast, UV and
cisplatin activation of
-PAK is independent of tyrosine kinase and
PI3-kinase activity. This suggests the involvement of more than one
pathway in the control of
-PAK activity in response to different
types of DNA damage.
To determine whether
-PAK activation in response to DNA damage was
a general feature of other members of the PAK family,
-PAK activity
was assayed after immunoprecipitation from control and treated 3T3-L1
cells (Fig. 4A). No activation
of
-PAK in response to IR or AraC was observed, indicating that
-PAK and
-PAK were differentially regulated. In contrast,
-PAK
was activated 2.4- and 1.8-fold, respectively, by cisplatin and UV.
|
It has been suggested that the stress-activated protein kinase JNK acts
downstream of PAK (5, 22, 23), even though this has been questioned
(24-26). Thus, we examined whether JNK was activated in response to
the different DNA-damaging treatments that were able to activate
-PAK. No activation of JNK was observed in 3T3-L1 cells 120 min
after irradiation with doses of 1, 5, or 100 Gy of IR, as determined by
phosphorylation of c-Jun (Fig. 4B). Longer incubation times
after irradiation (up to 6 h) did not induce JNK activation (data
not shown). The DNA-damaging drugs cisplatin and AraC also failed to
activate JNK significantly; in contrast, JNK was activated by UV (80 J/m2) in 3T3-L1 cells (Fig. 4B). The data is
consistent with results previously reported for NIH 3T3 cells, wherein
IR doses up to 100 Gy failed to activate JNK, although inducing c-Abl
activation or p53 accumulation (27). It is interesting to note that in 3T3-L1 cells, stress-inducing agents like the drugs anisomycin and
arsenite are able to activate JNK without any observable effect on
-PAK activity (data not shown).
| |
DISCUSSION |
|---|
|
|
|---|
-PAK is activated up to 5-fold during the early response to IR
in 3T3-L1 fibroblasts and U937 leukemia cells. This activation is time-
and dose-dependent, and correlates with an increase in the
amount of phosphorylated
-PAK present in the cells. Caspase cleavage
is not involved in the observed activation of
-PAK, because no
fragments of
-PAK are detected by Western blotting.
-PAK
activation by IR is dependent on tyrosine kinase and PI3-kinase activity, as shown by use of the inhibitors genistein and wortmannin. A
direct involvement of PI3-kinase (perhaps through activation of Cdc42)
in the response to IR cannot entirely be ruled out, but wortmannin
could also act through inhibition of the PI3-kinase-related enzymes
DNA-dependent protein kinase or ATM. These protein kinases are known to have a central role in the early response to agents that
induce DNA damage, such as IR (18). Other candidates for upstream
activators of
-PAK are the tyrosine kinases c-Abl and Lyn, which
have been shown to be activated in response to IR (28, 29). Because
-PAK activation in vitro requires autophosphorylation of
both the regulatory and catalytic domains of the enzyme (30-32), the
data suggest that autophosphorylation and
phosphorylation by other kinases may be involved in activation
in vivo.
-PAK is activated in response to different types of DNA damage such
as double strand breaks (IR), interstrand links (cisplatin), chain
termination (AraC), and pyrimidine dimer formation (UV). Like IR, AraC
activation of
-PAK is dependent on PI3-kinase and tyrosine kinase
activities; in contrast, activation by cisplatin and UV is not. This
suggests that
-PAK activity can be regulated by at least two
different signaling pathways; one activated by IR and AraC, which
requires PI3-kinase and tyrosine kinase activity, and another pathway
activated by cisplatin and UV, which is not significantly affected by
wortmannin and genistein. The data are consistent with the present
knowledge of the response to DNA damage in mammalian cells, where IR
and UV are known to activate different signaling pathways; the response
to IR is dependent on the PI3-kinase-related enzymes
DNA-dependent protein kinase and ATM, whereas the pathway activated by UV is not dependent on PI3-kinase-related enzymes (18).
Note that IR and AraC also activate the tyrosine kinase c-Abl, which is
not activated by UV (27, 28, 33), and cisplatin activates the tyrosine
kinase Abl (28), but not DNA-dependent protein kinase
(34).
Because all the studied DNA-damaging treatments stimulate
-PAK
activity,
-PAK activation may be a common event in the cellular response to DNA damage. In eukaryotic cells, all types of DNA damage
result in delayed progression through the cell cycle, with the
G2/M transition checkpoint playing a major role in
preventing cell division (15, 17, 18). Both
-PAK and X-PAK (a
-PAK Xenopus homologue) inhibit G2/M
transition and mitotic progression in frog oocytes and embryos (7, 35,
36). We propose that
-PAK activation in response to IR and other
DNA-damaging treatments is related to the cytostatic properties of the
kinase and is part of the common cytostatic response activated by
different types of DNA damage.
Currently
-PAK is the only mammalian PAK that, like the yeast PAK
homologue Ste20, has been related to cell cycle arrest (7, 37).
-PAK
is not activated by IR or treatment with AraC, but it is activated by
UV and cisplatin. Thus, the two different members of the PAK family can
be activated by specific DNA-damaging agents, but activation of
-PAK
is not a general response to DNA damage, as is
-PAK activation. In
contrast to
-PAK, JNK is activated primarily by UV.
This is the first time that members of the Ste20/PAK family of protein
kinases have been shown to be involved in the cellular response to
irradiation or treatment with DNA-damaging drugs. It is suggested that
-PAK activation by IR and DNA damage is important in the cytostatic
response elicited by these agents, as
-PAK has been shown previously
to induce cytostasis (7, 38). Additional studies are underway in our
laboratory to determine the requirements for activation of
-PAK in
response to IR and to define the role of the protein kinase in the
early response to DNA damage.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Gayle E. Woloshack, Argonne
National Laboratory, Chicago, IL, for introducing us to ionizing
radiation experimentation, and Dr. Andrew J. Grosovsky, University of
California, Riverside, CA, for the use of the 137Cs
-irradiator.
| |
FOOTNOTES |
|---|
* This work was supported by United States Public Health Service Grant GM26738.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biochemistry,
University of California, Riverside, CA 92521. Tel.: 909-787-4239; Fax:
909-787-3590; E-mail: jolinda.traugh@ucr.edu.
2 R. D. Rooney and J. A. Traugh, unpublished results.
3 A. Gatti and J. A. Traugh, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
PAK, p21-activated
protein kinase;
IR, ionizing radiation;
PI3-kinase, phosphoinositide
3-kinase;
AraC, cytosine
-D-arabinofuranoside;
cisplatin, cis-platinum(II)diammine dichloride;
JNK, c-Jun N-terminal
kinase;
Gy, gray.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Lim, L., Manser, E., Leung, T., and Hall, C. (1996) Eur. J. Biochem. 242, 171-185[Medline] [Order article via Infotrieve] |
| 2. | Sells, M. A., and Chernoff, J. (1997) Trends Cell Biol. 7, 162-167 |
| 3. | Knaus, U. G., and Bokoch, G. M. (1998) Int. J. Biochem. Cell Biol. 30, 857-862[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Rudel, T.,
and Bokoch, G. M.
(1997)
Science
276,
1571-1574 |
| 5. |
Lee, N.,
MacDonald, H.,
Reinhard, C.,
Halenbeck, R.,
Roulston, A.,
Shi, T.,
and Williams, L. T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13642-13647 |
| 6. |
Walter, B. N.,
Huang, Z.,
Jakobi, R.,
Tuazon, P. T.,
Alnemri, E. S.,
Litwack, G.,
and Traugh, J. A.
(1998)
J. Biol. Chem.
273,
28733-28739 |
| 7. |
Rooney, R. D.,
Tuazon, P. T.,
Meek, W. E.,
Carroll, E. J.,
Hagen, J. J.,
Gump, E. L.,
Monnig, C. A.,
Lugo, T.,
and Traugh, J. A.
(1996)
J. Biol. Chem.
271,
21498-21504 |
| 8. | Roig, J., Lytle, C., and Traugh, J. A. (1999) FASEB J. 13, 1579 (abstr.) |
| 9. | Sells, M. A., Knaus, U. G., Bagrodia, S., Ambrose, D. M., Bokoch, G. M., and Chernoff, J. (1997) Curr. Biol. 7, 202-210 |
| 10. | Manser, E., Huang, H. Y., Loo, T. H., Chen, X. Q., Dong, J. M., Leung, T., and Lim, L. (1997) Mol. Cell. Biol. 17, 1129-1143[Abstract] |
| 11. |
Zhao, Z. S.,
Manser, E.,
Chen, X. Q.,
Chong, C.,
Leung, T.,
and Lim, L.
(1998)
Mol. Cell. Biol.
18,
2153-2163 |
| 12. |
Dharmawardhane, S.,
Sanders, L. C.,
Martin, S. S.,
Daniels, R. H.,
and Bokoch, G. M.
(1997)
J. Cell Biol.
138,
1265-1278 |
| 13. |
Tsakiridis, T.,
Taha, C.,
Grinstein, S.,
and Klip, A.
(1996)
J. Biol. Chem.
271,
19664-19667 |
| 14. | King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., and Marshall, M. S. (1998) Nature 396, 180-183[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Bernhard, E. J., Maity, A., Muschel, R. J., and McKenna, W. G. (1995) Radiat. Environ. Biophys. 34, 79-83[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Woloschak, G. E. (1997) in Stress-inducible Processes in Higher Eukaryotic Cells (Koval, T. M., ed) , pp. 185-219, Plenum Press, New York |
| 17. | Rhind, N., and Russell, P. (1998) Curr. Opin. Cell Biol. 10, 749-758[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Wang, J. Y. (1998) Curr. Opin. Cell Biol. 10, 240-247[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Dérijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Sherman, S. E., and Lippard, S. J. (1987) J. Chem. Rev. 87, 1153-1181 |
| 21. | Kufe, D. W., Munroe, D., Herrick, D., Egan, E., and Spriggs, D. (1984) Mol. Pharmacol. 26, 128-134[Abstract] |
| 22. |
Bagrodia, S.,
Dérijard, B.,
Davis, R. J.,
and Cerione, R. A.
(1995)
J. Biol. Chem.
270,
27995-27998 |
| 23. |
Polverino, A.,
Frost, J.,
Yang, P.,
Hutchison, M.,
Neiman, A. M.,
Cobb, M. H.,
and Marcus, S.
(1995)
J. Biol. Chem.
270,
26067-26070 |
| 24. |
Teramoto, H.,
Coso, O. A.,
Miyata, H.,
Igishi, T.,
Miki, T.,
and Gutkind, J. S.
(1996)
J. Biol. Chem.
271,
27225-27228 |
| 25. | Minden, A., and Karin, M. (1997) Biochim. Biophys. Acta 1333, F85-F104[Medline] [Order article via Infotrieve] |
| 26. |
Zhou, K.,
Wang, Y.,
Gorski, J. L.,
Nomura, N.,
Collard, J.,
and Bokoch, G. M.
(1998)
J. Biol. Chem.
273,
16782-16786 |
| 27. | Liu, Z. G., Baskaran, R., Lea-Chou, E. T., Wood, L. D., Chen, Y., Karin, M., and Wang, J. Y. (1996) Nature 384, 273-276[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Kharbanda, S., Ren, R., Pandey, P., Shafman, T. D., Feller, S. M., Weichselbaum, R. R., and Kufe, D. W. (1995) Nature 376, 785-788[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Kharbanda, S.,
Yuan, Z. M.,
Rubin, E.,
Weichselbaum, R.,
and Kufe, D.
(1994)
J. Biol. Chem.
269,
20739-20743 |
| 30. |
Gatti, A.,
Huang, Z.,
Tuazon, P. T.,
and Traugh, J. A.
(1999)
J. Biol. Chem.
274,
8022-8028 |
| 31. | Tuazon, P. T., Chinwah, M., and Traugh, J. A. (1998) Biochemistry 37, 17024-17029[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Tuazon, P. T., Roig, J., Gatti, A., and Traugh, J. A. (1999) FASEB J. 13, A1490 |
| 33. |
Kharbanda, S.,
Pandey, P.,
Ren, R.,
Mayer, B.,
Zon, L.,
and Kufe, D.
(1995)
J. Biol. Chem.
270,
30278-30281 |
| 34. | Turchi, J. J., Patrick, S. M., and Henkels, K. M. (1997) Biochemistry 36, 7586-7593[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Faure, S., Vigneron, S., Dorée, M., and Morin, N. (1997) EMBO J. 16, 5550-5561[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Faure, S.,
Vigneron, S.,
Galas, S.,
Brassac, T.,
Delsert, C.,
and Morin, N.
(1999)
J. Biol. Chem.
274,
3573-3579 |
| 37. | Herskowitz, I. (1995) Cell 80, 187-197[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Huang, Z., and Traugh, J. A. (1999) FASEB J. 13, 1578 (abstr.) |
This article has been cited by other articles:
![]() |
S. J. Coniglio, S. Zavarella, and M. H. Symons Pak1 and Pak2 Mediate Tumor Cell Invasion through Distinct Signaling Mechanisms Mol. Cell. Biol., June 15, 2008; 28(12): 4162 - 4172. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Derdak, N. M. Mark, G. Beldi, S. C. Robson, J. R. Wands, and G. Baffy The Mitochondrial Uncoupling Protein-2 Promotes Chemoresistance in Cancer Cells Cancer Res., April 15, 2008; 68(8): 2813 - 2819. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Escriva, S. Peiro, N. Herranz, P. Villagrasa, N. Dave, B. Montserrat-Sentis, S. A. Murray, C. Franci, T. Gridley, I. Virtanen, et al. Repression of PTEN Phosphatase by Snail1 Transcriptional Factor during Gamma Radiation-Induced Apoptosis Mol. Cell. Biol., March 1, 2008; 28(5): 1528 - 1540. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Jung and J. A. Traugh Regulation of the Interaction of Pak2 with Cdc42 via Autophosphorylation of Serine 141 J. Biol. Chem., December 2, 2005; 280(48): 40025 - 40031. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Orton, J. Ling, A. J. Waskiewicz, J. A. Cooper, W. C. Merrick, N. L. Korneeva, R. E. Rhoads, N. Sonenberg, and J. A. Traugh Phosphorylation of Mnk1 by Caspase-activated Pak2/{gamma}-PAK Inhibits Phosphorylation and Interaction of eIF4G with Mnk J. Biol. Chem., September 10, 2004; 279(37): 38649 - 38657. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. S. Miah, K. Sada, P. T. Tuazon, J. Ling, K. Maeno, S. Kyo, X. Qu, Y. Tohyama, J. A. Traugh, and H. Yamamura Activation of Syk Protein Tyrosine Kinase in Response to Osmotic Stress Requires Interaction with p21-Activated Protein Kinase Pak2/{gamma}-PAK Mol. Cell. Biol., January 1, 2004; 24(1): 71 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kim, P. Yang, P. Catanuto, F. Verde, H. Lai, H. Du, F. Chang, and S. Marcus The Kelch Repeat Protein, Tea1, Is a Potential Substrate Target of the p21-activated Kinase, Shk1, in the Fission Yeast, Schizosaccharomyces pombe J. Biol. Chem., August 8, 2003; 278(32): 30074 - 30082. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Huang, J. Ling, and J. A. Traugh Localization of p21-activated Protein Kinase gamma -PAK/Pak2 in the Endoplasmic Reticulum Is Required for Induction of Cytostasis J. Biol. Chem., April 4, 2003; 278(15): 13101 - 13109. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Gallagher, S. Xu, C. Moomaw, C. A. Slaughter, and M. H. Cobb Binding of JNK/SAPK to MEKK1 Is Regulated by Phosphorylation J. Biol. Chem., November 22, 2002; 277(48): 45785 - 45792. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Roig, P. T. Tuazon, P. A. Zipfel, A. M. Pendergast, and J. A. Traugh Functional interaction between c-Abl and the p21-activated protein kinase gamma -PAK PNAS, December 19, 2000; 97(26): 14346 - 14351. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Roig, Z. Huang, C. Lytle, and J. A. Traugh p21-activated Protein Kinase gamma -PAK Is Translocated and Activated in Response to Hyperosmolarity. IMPLICATION OF Cdc42 AND PHOSPHOINOSITIDE 3-KINASE IN A TWO-STEP MECHANISM FOR gamma -PAK ACTIVATION J. Biol. Chem., May 26, 2000; 275(22): 16933 - 16940. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Jakobi, E. Moertl, and M. A. Koeppel p21-activated Protein Kinase gamma -PAK Suppresses Programmed Cell Death of BALB3T3 Fibroblasts J. Biol. Chem., May 11, 2001; 276(20): 16624 - 16634. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Reeder, I. G. Serebriiskii, E. A. Golemis, and J. Chernoff Analysis of Small GTPase Signaling Pathways Using p21-activated Kinase Mutants That Selectively Couple to Cdc42 J. Biol. Chem., October 26, 2001; 276(44): 40606 - 40613. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||